SKYE
Skye Bioscience, Inc.
There isn't enough reported data to score SKYE yet.
SKYE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
SKYE's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
SKYE PE Valuation
SKYE has no meaningful PE right now: it lost money over the past year.
SKYE Forward outlook
There aren't enough analyst estimates for SKYE to show an outlook.
SKYE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$10.24 | -$1.68 |
| Q1 2026 | -$11.60 | -$4.96 |
| Q4 2025 | -$11.28 | -$5.44 |
| Q3 2025 | -$10.32 | -$1.99 |
| Q2 2025 | -$8.56 | +$24.33 |
| Q1 2025 | -$6.64 | +$24.65 |
| Q4 2024 | -$5.84 | +$44.01 |
| Q3 2024 | -$8.33 | +$57.03 |
SKYE is still losing money, but far less than before: $10.24 per share over the past year, against $200.00 at its worst in late 2019.
SKYE Quarterly Revenue
SKYE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$7.1M | +$3.6M |
| Q1 2026 | -$8.6M | +$633.9K |
| Q4 2025 | -$9.8M | -$1.5M |
| Q3 2025 | -$13.4M | -$6.6M |
| Q2 2025 | -$10.7M | -$3.6M |
| Q1 2025 | -$9.2M | -$4.5M |
| Q4 2024 | -$8.2M | -$4.4M |
| Q3 2024 | -$6.8M | -$2.7M |
SKYE has burned cash in almost every quarter: −$39M over the past year, against −$35M the year before.
SKYE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1.6K shares |
| 1 year | +0.1% | +4.4K shares |
| 3 years | +921% | +4.5M shares |
| 5 years | +2846% | +4.8M shares |
| Available history | +7361% | +4.9M shares |
SKYE has 5M diluted shares, about the same as a year ago.
SKYE Net Leverage
SKYE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SKYE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 3.2 | Oversold |
SKYE's weekly RSI is 24 (oversold) and its Stochastic is 3 (oversold).
SKYE PE vs Healthcare Sector
| Metric | SKYE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SKYE has no meaningful PE right now: it lost money over the past year.
SKYE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.44 | 25% below |
| 20 week MA | $2.77 | 61% below |
| 50 week MA | $5.07 | 79% below |
| 100 week MA | $13.2 | 92% below |
| 200 week MA | $30.3 | 96% below |
SKYE is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
SKYE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $360.0 | $92.0 | -74% |
| 2021 | $92.0 | $106.0 | +15% |
| 2022 | $106.0 | $26.0 | -75% |
| 2023 | $26.0 | $21.8 | -16% |
| 2024 | $21.8 | $19.7 | -9.6% |
| 2025 | $19.7 | $6.40 | -67% |
| 2026 YTD | $6.40 | $1.08 | -83% |
SKYE has finished four years in a row lower, and it's down 83% so far in 2026.